![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GENENTECH & INOTEK ENTER INTO EXCLUSIVE GLOBAL STRATEGIC ALLIANCE FOR THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF PARP INHIBITORS FOR CANCER
GENENTECH & INOTEK ENTER INTO EXCLUSIVE GLOBAL STRATEGIC ALLIANCE FOR THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF PARP INHIBITORS FOR CANCER
July 25, 2006
Genentech, Inc. and Inotek Pharmaceuticals Corporation announced that they have entered into an exclusive global collaboration to discover, develop, manufacture and commercialize inhibitors of poly (ADP-ribose) polymerase (PARP) for the potential treatment of cancer. PARP is a nuclear enzyme within cells that directs the repair of damaged DNA via the activation and recruitment of DNA repair enzymes and has applications for the treatment of oncology and cardiovascular conditions. Biotech Intelligence (http://www.biotech-intelligence.com/html/html/pool_3/e29fc10da6e8fd9013c80e4171bd32dd.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct